AgomAb Therapeutics CFO buys 10,000 common shares

Each American Depositary Share currently represents one common share, and the reported purchases were directly held.

(Neutral)

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AgomAb Therapeutics NV (AGMB) Chief Financial Officer Pierre Thadee Victor Kemula purchased 10,000 common shares directly on October 6, 2026, across three reported transactions: 3,000 at $8.67 per share, 5,000 at $8.57, and 2,000 at $8.54. No Rule 10b5-1 plan is reported. The common shares may be represented by American Depositary Shares, each currently representing one common share.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 3 txns

Insider Kemula Pierre Thadee Victor

Role Chief Financial Officer

Bought 10,000 shs ($86K)

Type	Security	Shares	Price	Value
Purchase	Common shares ^F1	3,000	$8.67	$26K
Purchase	Common shares ^F1	5,000	$8.57	$43K
Purchase	Common shares ^F1	2,000	$8.54	$17K

Holdings After Transaction: Common shares — 10,000 shares (Direct)

Footnotes (1)

F1. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

Key Figures

Common shares purchased: 3,000 shares Price per share: $8.67 Common shares purchased: 5,000 shares +3 more

6 metrics

Common shares purchased 3,000 shares Pierre Thadee Victor Kemula; October 6, 2026

Price per share $8.67 Purchase of 3,000 common shares on October 6, 2026

Common shares purchased 5,000 shares Pierre Thadee Victor Kemula; October 6, 2026

Price per share $8.57 Purchase of 5,000 common shares on October 6, 2026

Common shares purchased 2,000 shares Pierre Thadee Victor Kemula; October 6, 2026

Price per share $8.54 Purchase of 2,000 common shares on October 6, 2026

Key Terms

American Depositary Shares

1 terms

American Depositary Shares financial

"may be represented by American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AGMB shares did the CFO buy and at what prices?

Pierre Thadee Victor Kemula, AgomAb Therapeutics NV’s Chief Financial Officer, purchased 10,000 common shares on October 6, 2026: 3,000 at $8.67 per share, 5,000 at $8.57, and 2,000 at $8.54. No Rule 10b5-1 plan is reported.

How many AGMB common shares does each ADS represent?

Each American Depositary Share currently represents one common share. AgomAb’s common shares may be represented by American Depositary Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/07/2026 - 08:47 AM Accepted by SEC EDGAR 10/07/2026 - 08:47 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kemula Pierre Thadee Victor

(Last)

(First)

(Middle)

C/O AGOMAB THERAPEUTICS NV

POSTHOFLEI 1/6 2600

(Street)

ANTWERPEN

00000

(City)

(State)

(Zip)

BELGIUM

(Country)

2. Issuer Name and Ticker or Trading Symbol
AgomAb Therapeutics NV [ AGMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common shares⁽¹⁾	10/06/2026		P		3,000	A	$8.67	3,000	D
Common shares⁽¹⁾	10/06/2026		P		5,000	A	$8.57	8,000	D
Common shares⁽¹⁾	10/06/2026		P		2,000	A	$8.54	10,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

	Ellen Lefever, Attorney-in-fact	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR